## JNJ: Johnson & Johnson - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.7% below STRENGTH zone (3.0-6.0%); PEG 1.12 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($201.29)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 1)

**1. J&J junks $1.2B eczema therapy while Genmab clears out cancer drug**
- Source: Fierce Biotech | 20260102T140746 | Bearish | Relevance: 100%
- Johnson & Johnson has terminated development of its $1.25 billion eczema therapy, JNJ-95475939, after interim analysis of a phase 2b study did not meet efficacy criteria for atopic dermatitis. Meanwhile, Genmab is halting work on its cancer therapy, acasunlimab, despite "encouraging" data, to focus on late-stage portfolio opportunities. This decision follows BioNTech's earlier withdrawal from the acasunlimab partnership due to portfolio strategy.

**2. Johnson & Johnson declares $1.30 per share dividend for Q1 2026**
- Source: Investing.com | 20260102T131004 | Bullish | Relevance: 100%
- Johnson & Johnson has announced a quarterly cash dividend of $1.30 per share for the first quarter of 2026, payable on March 10, 2026, to shareholders of record on February 24, 2026. This dividend declaration follows recent strategic acquisitions, including Halda Therapeutics, and FDA approvals for its medical technologies and treatments. The company's recent activities have led to analyst price target increases, reflecting ongoing growth and regulatory advancements.

**3. Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026**
- Source: Business Wire | 20260102T130158 | Bullish | Relevance: 100%
- Johnson & Johnson (NYSE: JNJ) has declared a cash dividend of $1.30 per share for the first quarter of 2026. This dividend is payable on March 10, 2026, to shareholders of record as of February 24, 2026, with the ex-dividend date also being February 24, 2026. The announcement reflects the company's consistent return of value to its shareholders.

**4. JP Morgan 2026 Preview: Johnson & Johnson Prepares a Fireside Chat**
- Source: Pharmaceutical Executive | 20251231T111352 | Bullish | Relevance: 100%
- Johnson & Johnson is set to host a fireside chat at the upcoming 44th Annual JP Morgan Healthcare Conference, where it may unveil significant acquisition plans for 2026. This follows strategic acquisitions in 2024 and 2025, including Intra-Cellular Therapies for $14.6 billion to bolster its neuroscience portfolio and Ambrx for nearly $2 billion to advance cancer treatment with ADC technology. These moves underscore J&J's focus on expanding its innovative medicine business and addressing critical unmet medical needs.

**5. Barclays Keeps Their Hold Rating on Johnson & Johnson (JNJ)**
- Source: The Globe and Mail | 20251231T080819 | Neutral | Relevance: 100%
- Barclays analyst Matt Miksic reiterated a Hold rating on Johnson & Johnson (JNJ) with a $217.00 price target. This comes as the company reported strong Q3 revenues of $23.99 billion and a net profit of $5.15 billion, exceeding last year's figures. Insider sentiment is neutral, though one director recently purchased 1,250 shares.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 7, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-30 | Barclays | $217 | $197 | +10% |
| 2025-12-19 | Goldman Sachs | $240 | $213 | +13% |
| 2025-12-15 | B of A Securiti | $220 | $204 | +8% |
| 2025-12-12 | Morgan Stanley | $197 | $190 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-30 | Barclays | main | Equal-Weight |
| 2025-12-19 | Goldman Sachs | main | Buy |
| 2025-12-15 | B of A Securiti | main | Neutral |
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 5 ($3.81M) |
| Sells | 6 ($0.64M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 36.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.2%)
- Blackrock Inc.: 8.6% (+1.7%)
- State Street Corpora: 5.5% (-0.4%)
- JPMORGAN CHASE & CO: 4.9% (+109.0%)
- Geode Capital Manage: 2.3% (-7.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 7 raises (avg +9%) could attract flows.
- Momentum building: MRS_10 improving +2.8% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.12 suggests fair value with growth premium. Forward P/E 18.0x stretched relative to 6% growth. Quality metrics strong (ROE 34%, margin 27%). Balance sheet: $8.4B free cash flow. Analyst sentiment positive (7 raises, avg +9%). Insider buying signal ($3.8M), management confidence. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $499.6B |
| Beta | 0.35 |
| 52W Range | $140.68 - $215.19 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.12 |
| Forward P/E | 18.0 |
| Current P/E | 19.1 |
| YoY Growth | 6.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -2.0% to 0.7% (+2.8% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.3pp (needs >3.0% for momentum thesis). MRS_5 at 0.7% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.67), momentum weakening. RSI neutral at 56. OFD pattern: +DLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.72% (CS: 50) | Neutral |
| RSI_14 | 55.8 | Neutral |
| MACD Histogram | -0.67 | Bearish |
| vs SMA20 | 1.002x | Above |
| vs SMA50 | 1.036x | Above |
| vs SMA200 | 1.191x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $207.35
- **Stop Loss:** $201.29 (2.9% risk)
- **Target:** $213.41 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 237
- **Position Value:** $49,141.95
- **Portfolio %:** 49.14%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-01-21 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.76 | $2.80 | +1.5% |
| 2025Q2 | $2.68 | $2.77 | +3.2% |
| 2025Q1 | $2.58 | $2.77 | +7.4% |
| 2024Q4 | $2.01 | $2.04 | +1.4% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_10*